Background: Andhra Pradesh state has the highest HIV burden in India. Andhra Pradesh AIDS Consortium (APAIDSCON) the largest public health partnership a network of 20 medical colleges established to address HIV AIDS in India was spearheaded by SHARE India and funded in part by United States Centers for Disease Control & Prevention Cooperative agreement # U62/CCU025160-02.
-2010
Methods & Materials: Results of Interventions to reduce stigma and discrimination were analyzed. Both quantitative and qualitative methods were used. Adapted questionnaire on stigma and discrimination was used. Methods included In Depth Interviews with key stakeholders and patients to understand reporting of Stigma & Discrimination. Focus Group Discussions were used. Ethics committee approval was obtained.
Results: The qualitative data indicated that stigma and discrimination present in the consortium among Health Care Providers due to the "fear element" was substantially decreased due to measures taken by the project like training and sensitization programs for HCPs, guidelines and protocol implementation to reduce stigma and discrimination, prevention of segregation i.e. separate bed or special identification marks during admission, staff compensation and facilitation of universal precautions. The qualitative data demonstrated that management of the sampled private hospitals never placed hurdles to admitting HIV positive cases. This created a conducive environment against stigma and discrimination. Instructions were given not to mention HIV positive status in patient's case record. Segregation of HIV positive patients for routine care was eliminated. After conclusion of the project follow up interviews of 117 in-patients from four of the sampled institutes demonstrated persistence of best practices with more than 96% of the PLHIV responding that there is no differential treatment or denial of treatment in these sites.
Conclusion: Across the APAIDSCON consortium persistent efforts to remove the knowledge barriers had a salutary effect; HIV services could be provided without stigma and discrimination in the private sector. Grounded efforts with the managements both in private and public sector yield sustained results long after the intervention ended. Background: Analysis of micro RNA(miRNAs) based regulatory networks in infectious diseases is a challenging task in the era of post genomics and prediction of the miRNAs associated with pharmacogenomics of acquired Immune Deficiency Syndrome (AIDS) is an initiation towards the miRNA based therapy for AIDS.
Methods & Materials: Initially we have taken the list of human genes associated with AIDS from PharmG-KB and further we have analyzed the network of human miRNAs which are associated with AIDS related genes from EnrichR. Finally we performed statistical analysis like P value, Z test and combined score of Students T test and ANNOVA to analyze the significance of those predicted miRNAs towards the Human Immune Virus (HIV) related genes.
Results: PharmG KB contains 6 genes (ABCB1, CYCSP5, G6PD, GSTM1, NAT2 and NR1I2) which are associated with the Pharmacogenomics of AIDS. EnrichR has predicted 6 miRNAs (hsa-miR-18a, hsa-miR-1, hsa-miR-206, hsa-miR-24, hsa-miR-125a and hsa-miR125b) which are related to AIDS related genes. Based on the statistical analysis, it has been found that hsa-miR-18a has a minimum P value and Z score of 0.0370 & -1.82 respectively. Association of hsa-miR-18a with HIV related genes shows a 4 fold increase when compared with hsa-miR-1 and hsa-miR-206. Similarly the association of hsa-miR-24 shows a 3 fold decrease when compared with hsa-miR-18a and finally, hsa-miR-125a and hsa-miR-125b has a 5 fold decrease when compared with hsa-miR-18a.
Conclusion: Based on the statistical analysis of gene and miRNA regulated networks, it was found that hsa-miR-18a show a good statistical significance towards genes which are related to AIDS and in future, hsa-miR-18a may turn out to be a potential target for the miRNA based therapeutics of AIDS. At present, we have applied the above mentioned methodology for AIDS and in future, this methodology will also be applied to other infectious diseases.
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